Company Ticker News February 4, 2022Regeneron Reports Fourth Quarter and Full Year 2021 Financial and Operating Results 0 0 Share
Company Ticker News February 3, 2022Why Regeneron (REGN) Might Surprise This Earnings Season 0 0 Share
Press Release February 1, 2022Positive Dupixent® (dupilumab) Data Across Five Diseases with Underlying Type 2 Inflammation to be Presented at 2022 AAAAI Annual Meeting 0 0 Share
Company Ticker News January 31, 2022Regeneron (REGN) Withdraws sBLA for Libtayo in Cervical Cancer 0 0 Share
Company Ticker News January 31, 2022Will Eylea, Dupixent Aid Regeneron's (REGN) Q4 Earnings? 0 0 Share
Company Ticker News January 31, 2022CHMP Backs Sanofi-Regeneron's Dupixent For Asthma Patients Aged 6 - 11 Years With Type 2 Inflammation 0 0 Share
Press Release January 31, 2022CHMP Recommends Approval of Dupixent® (dupilumab) for Children Aged 6 to 11 Years with Severe Asthma with Type 2 Inflammation 0 0 Share
Press Release January 31, 2022CHMP recommends approval of Dupixent® (dupilumab) for children aged 6 to 11 years with severe asthma with type 2 inflammation 0 0 Share
Company Ticker News January 28, 2022Regeneron, Sanofi Withdraw FDA Application For Libtayo's Expanded Use 0 0 Share
Company Ticker News January 28, 2022Regeneron, Sanofi withdraw application for Libtaya as a cervical cancer treatment in the U.S. 0 0 Share
